STOCK TITAN

Cerenome: No dose-limiting toxicities in 10 patients

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Cerenome, Inc. (CNSY) reported interim data from its ongoing open-label Phase 1 ReSPECT-LM study of repeat intraventricular REYOBIQ for leptomeningeal metastases. Among the first 10 patients, no dose-limiting toxicities or adverse events leading to treatment discontinuation were reported; one had Grade 3 treatment-related nausea that resolved within five days. One patient received three 26.4 mCi administrations (79.2 mCi total activity), with an estimated cumulative LM-compartment absorbed dose of 207 Gy. The median within-patient coefficient of variation in absorbed dose per mCi was 8%.

Among evaluable patients, LM progression was not documented at three or six months (0/5 at each landmark); it was documented in 1 of 4 by nine months. These are descriptive landmark findings, not progression-free survival estimates, and do not establish a progression-free or overall survival benefit; patients differed in cancers, treatment histories and follow-up, and some received concurrent systemic therapy. Dose escalation and enrollment continue; Cerenome targets a Phase 2 randomized study in 2027, subject to continued clinical progress and regulatory alignment. REYOBIQ is investigational and not approved by FDA or another regulatory authority.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Patients treated 10 patients First patients reported in the interim ReSPECT-LM data
Total administered activity 79.2 mCi One patient received three 26.4 mCi administrations
Estimated cumulative LM-compartment absorbed dose 207 Gy First patient to complete three 26.4 mCi administrations
Median within-patient coefficient of variation in absorbed dose per mCi 8% Repeat administrations
Three-month LM progression 0/5 evaluable patients By the three-month landmark
Six-month LM progression 0/5 evaluable patients By the six-month landmark
Nine-month LM progression 1/4 evaluable patients By the nine-month landmark
Median blood-derived marrow absorbed dose 0.023 Gy per administration Range: 0.010–0.41 Gy per administration
leptomeningeal metastases medical
"patients with leptomeningeal metastases"
Leptomeningeal metastases occur when cancer cells spread to the thin layers of tissue covering the brain and spinal cord, similar to how weeds can invade the surface layer of soil. This condition often indicates advanced disease and can lead to serious neurological problems. For investors, the presence of such metastases may signal challenges in treatment options and can impact the outlook for related healthcare companies or research developments.
intraventricular administration medical
"repeated intraventricular administration of REYOBIQ"
dosimetry medical
"treatment exposure, safety, dosimetry"
Dosimetry is the measurement and calculation of how much ionizing radiation is absorbed by people, tissues, or devices, similar to a thermostat tracking temperature in different rooms to know where and how much heat is present. Investors should care because accurate dosimetry underpins safety, treatment effectiveness, regulatory approval, and liability for products and services that use radiation—affecting market access, costs, and commercial risk.
Ommaya reservoir medical
"delivered into the LM compartment through an Ommaya reservoir"
coefficient of variation technical
"median within-patient coefficient of variation, 8%"
The coefficient of variation is a statistical measure that divides the standard deviation of a series of numbers by their mean, often shown as a percentage, to express variability relative to the average. It matters to investors because it lets you compare how much risk or fluctuation exists per unit of return across different assets or time periods—like comparing fuel efficiency (miles per gallon) rather than raw miles or gallons alone.
cerebrospinal fluid (CSF) medical
"cerebrospinal fluid (CSF) tumor-cell findings"
Cerebrospinal fluid (CSF) is a clear liquid that surrounds and cushions the brain and spinal cord, providing protection and helping to remove waste. Although it is a medical term, in a financial context, understanding how resources and support flow within a system can be similar to how CSF circulates and maintains the health of the nervous system. Recognizing such fundamental processes can offer insights into the stability and resilience of broader systems, including financial markets.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What safety results did Cerenome report for REYOBIQ in CNSY's ReSPECT-LM study?

Among the first 10 patients, no dose-limiting toxicities or adverse events leading to treatment discontinuation were reported. One patient had Grade 3 treatment-related nausea that resolved within five days; the only serious adverse event, shortness of breath in one patient, was considered unrelated to treatment.

How many evaluable ReSPECT-LM patients had progression at each landmark?

LM progression was not documented by three or six months among evaluable patients (0/5 at each landmark); progression was documented in 1 of 4 evaluable patients by nine months. Cerenome described these as landmark findings, not progression-free survival estimates; patients with insufficient follow-up or certain deaths before a landmark were excluded.

What cumulative REYOBIQ dose did Cerenome report in CNSY's ReSPECT-LM study?

One patient received three 26.4 mCi administrations, for a total administered activity of 79.2 mCi. The estimated cumulative absorbed dose to the leptomeningeal compartment was 207 Gy.

What dosing levels and intervals is the ReSPECT-LM study evaluating?

The study evaluates dose levels of 13.2, 26.4 and 44.1 mCi, with dosing intervals of every 14, 28 or 56 days across eight planned cohorts. Each participant is scheduled for three administrations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0001095981false00010959812026-11-162026-11-16

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 16, 2026

 

 

CERENOME, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-34375

33-0827593

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

6420 LEVIT GREEN BOULEVARD

Suite 310

 

Houston, Texas

 

77021

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (737) 255-7194

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.001 per share

 

CNSY

 

Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 

 


 

Item 8.01

Other Events.

 

On November 16, 2026, Cerenome, Inc. issued a press release regarding its report of interim ReSPECT-LM data at the 2026 Society for Neuro-Oncology Annual Meeting. The press release contains statements intended as “forward-looking statements” which are subject to the cautionary statements about forward-looking statements set forth therein. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference.

 

Item 9.01

Financial Statements and Exhibits.

 

(d) Exhibits.

Exhibit
Number

Description

99.1

Press Release dated November 16, 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)


 

 


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

CERENOME, INC.

 

 

 

 

Date:

November 16, 2026

By:

/s/ Marc H. Hedrick, M.D.

 

 

 

Name: Marc H. Hedrick, M.D.
Title: President and Chief Executive Officer

 

 


Exhibit 99.1

Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting

 

No dose-limiting toxicities in the first 10 patients; consistent and reliable dosing of a targeted radiopharmaceutical; early disease control signal in line with existing data

 

HOUSTON, November 16, 2026 (GLOBE NEWSWIRE) — Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted radiopharmaceuticals, and artificial intelligence, today announced interim data from its ongoing ReSPECT-LM study of repeated intraventricular dosing of REYOBIQ™ (rhenium Re186 obisbemeda) in patients with leptomeningeal metastases (LM). The data were presented as a poster on November 13, 2026, during the Society for Neuro-Oncology (SNO) 31st Annual Meeting and Education Day.

The poster reports treatment exposure, safety, dosimetry, LM progression status, and cerebrospinal fluid (CSF) tumor-cell findings for the first 10 patients treated. No dose-limiting toxicities or adverse events leading to treatment discontinuation have been reported. To date, one patient has received three 26.4 mCi doses, for a total administered activity of 79.2 mCi. This exceeds the highest activity given as a single administration in the prior single-dose ReSPECT-LM study (75 mCi). Furthermore, imaging showed the radiation dose delivered to the LM compartment was consistent from one treatment to the next within each patient, varying by a median of 8%. These levels are consistent with previously reported Phase 1 single-dose data. Dose escalation is ongoing.

No LM progression was documented by the three- and six-month landmarks among evaluable patients (0/5 at each landmark), and progression was documented in 1 of 4 evaluable patients by nine months.

“These interim findings support the feasibility and early tolerability of fractionated REYOBIQ dosing as a way to deliver a higher cumulative radiation dose to the LM compartment,” said Eric J. Daniels, M.D., Cerenome’s Chief Operating Officer. “The LM progression findings among evaluable patients are encouraging, alongside the absence of dose-limiting toxicities to date and consistent radiation delivery across repeat administrations. Our focus now is on continued dose escalation and enrollment to define recommended multiple-dose regimens in support of a future randomized study.”

Interim ReSPECT-LM Findings

Of the 10 patients, six received 13.2 mCi per administration and four received 26.4 mCi per administration. Primary cancers included melanoma (4), breast cancer (3), non-small cell lung cancer (1), ovarian cancer (1), and neuroendocrine cancer (1). Nine patients had received prior LM therapy, and three were receiving concurrent systemic treatment.

•
Safety: No dose-limiting toxicities or adverse events leading to discontinuation have been observed. One patient had Grade 3 treatment-related nausea, which resolved within five days. The only serious adverse event, shortness of breath occurring in a single subject, was considered unrelated to treatment. All 10 patients had at least one treatment-emergent adverse event; the most common were nausea (60%), headache (40%), decreased lymphocyte count (40%), and decreased white blood cell count (40%).
•
Landmark LM progression findings: No LM progression was documented by three or six months among evaluable patients (0/5 at each landmark). By nine months, LM progression was documented in 1 of 4 evaluable patients. Evaluability was determined by principal investigator review of available records, based on documented progression on or before the landmark or adequate disease-assessment follow-up establishing LM status through that landmark. Patients with insufficient follow-up, or who died from primary disease before the landmark without prior LM progression, were excluded. These descriptive findings are not progression-free survival estimates.
•
CSF tumor-cell findings: Serial monitoring with Cerenome’s CNSide® documented tumor-cell reductions in individual patients. Three patients with detectable tumor cells at baseline later had samples with zero tumor cells/mL. Two of them remained at zero tumor cells/mL at their latest assessments, 9.2 and 2.3 months after the first dose, respectively. The third later had a rise in tumor-cell counts and MRI-confirmed LM progression, nearly 4 months after the third dose of REYOBIQ.

 


 

•
High cumulative absorbed doses: The first patient to complete three administrations at 26.4 mCi per dose received an estimated cumulative LM compartment absorbed dose of 207 Gy, with no dose-limiting toxicities. Five patients completing three administrations at the lowest dose level, 13.2 mCi per dose, received cumulative LM compartment absorbed doses of 85–137 Gy, again consistent with previously observed Phase 1 data.
•
Consistent repeat-dose delivery: In patients who received repeat administrations, the absorbed dose per mCi varied little from dose to dose (median within-patient coefficient of variation, 8%), as did the CSF effective half-life (12%). Dosimetry was consistent with the prior single-dose ReSPECT-LM experience, supporting the feasibility of repeat dosing. SPECT/CT imaging in the patient who completed three 26.4 mCi administrations showed a similar distribution of activity after each dose.

 

•
Low estimated bone marrow exposure: The median blood-derived marrow absorbed dose was 0.023 Gy per administration (range, 0.010–0.41 Gy). This low level of blood exposure is important to avoid potential cytopenias and further supports continued investigation of local LM compartmental delivery.

“The lack of documented LM progression among evaluable patients at the three- and six-month landmarks is early and encouraging, particularly in a population in which most patients had received prior LM therapy,” said Andrew J. Brenner, M.D., Ph.D., Professor of Medicine at Mays Cancer Center at UT Health San Antonio and lead author of the poster. “The ability to deliver substantial cumulative radiation doses with consistent repeat-dose delivery and low estimated marrow exposure supports further evaluation. These findings remain preliminary, and continued enrollment and follow-up are needed to determine the clinical activity of this regimen.”

These preliminary findings come from an ongoing, open-label dose-escalation study. Patients had different primary cancers, treatment histories, and lengths of follow-up, and some received concurrent systemic therapy. The landmark analyses include only patients evaluable at each time point and do not establish a progression-free or overall survival benefit.

As previously announced, Cerenome is targeting a Phase 2 randomized study in 2027, subject to continued clinical progress and regulatory alignment.

Poster Presentation

Abstract Code

CTNI-40

Poster Title

Repeated Intraventricular Rhenium-186 Obisbemeda (186RNL) in Leptomeningeal Metastases: Interim Dosimetry, Safety, and CSF Tumor Cell Response From the ReSPECT-LM Multiple-Dose Study

Date and Time

Friday, November 13, 2026, 7:30-9:30 p.m. ET

Location

Exhibit Hall D & E, Pennsylvania Convention Center, Philadelphia

 

About ReSPECT-LM

ReSPECT-LM (NCT07098806) is an open-label, multicenter Phase 1 study of repeated intraventricular administration of REYOBIQ in adults with LM from solid tumors. REYOBIQ is delivered into the LM compartment through an Ommaya reservoir. The study is evaluating three dose levels (13.2, 26.4 and 44.1 mCi) and three dosing intervals (every 14, 28 or 56 days) across eight planned cohorts, with three administrations per participant. It is designed to assess safety, dosimetry and activity, and to identify a recommended multiple-dose regimen.

 

About REYOBIQ™

REYOBIQ (rhenium Re186 obisbemeda) is an investigational injectable radiotherapeutic in which the radioisotope rhenium-186 is chelated and trapped inside a nanoliposome. It is designed to deliver targeted, high-dose beta radiation directly to tumors through local delivery, such as convection-enhanced delivery or an intraventricular (Ommaya) catheter, while keeping exposure to the rest of the body low.

 

REYOBIQ is being evaluated for the treatment of leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers in the ReSPECT-LM, ReSPECT-GBM, and ReSPECT-PBC clinical trials, respectively.


 

Results from the multicenter Phase 1 ReSPECT-GBM trial were published in Nature Communications in 2025 (Brenner AJ, et al. Nat Commun. 2025;16:2079). REYOBIQ is investigational and has not been approved by the U.S. Food and Drug Administration or any other regulatory authority for any use. ReSPECT-GBM is supported by an award from the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), and ReSPECT-LM is funded by a $17.6 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT). The Company's ReSPECT-PBC clinical trial for pediatric brain cancer is supported by a $3 million grant from the U.S. Department of Defense's Peer Reviewed Cancer Research Program.

 

About Cerenome

Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The CNSide® CSF diagnostics platform combines cellular and molecular testing to support the detection, characterization, and longitudinal assessment of cancers involving the CNS.

 

Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation.

 

By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value. For more information, visit https://www.cerenome.com.

 

Forward-Looking Statements

 

This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding commercialization, clinical trials and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expected,” “planning,” “future,” “targeting,” “continue,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the development and clinical utility of the ReSPECT-LM study and future randomized studies regarding ReSPECT-LM.

 

 

 

Investor Contact

CORE IR

IR@cerenome.com

 


Filing Exhibits & Attachments

2 documents

Keep reading